Cite
HARVARD Citation
Assenat, E. et al. (2021). Phase II study evaluating the association of gemcitabine, trastuzumab and erlotinib as first‐line treatment in patients with metastatic pancreatic adenocarcinoma (GATE 1). International journal of cancer. 148 (3), pp. 682-691. [Online].